Discounted Cash Flow
Arbutus Biopharma Corp.
—
—
⚠ Cash flow predictability 61/100 (moderate) —
FCF YoY std dev 43%,
net income 50% (full history)
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.1m | $-279.0m | $-44.9m | -25765.5% | $-7.24 |
| 2017 | $7.8m (617.6%) | $-61.3m (78.0%) | $-40.6m (9.7%) | -788.9% (96.9%) | $-1.56 (78.5%) |
| 2018 | $4.3m (-44.4%) | $-41.4m (32.4%) | $-50.1m (-23.4%) | -959.8% (-21.7%) | $-1.21 (22.4%) |
| 2019 | $4.4m (1.1%) | $-111.6m (-169.4%) | $-52.0m (-3.8%) | -2557.4% (-166.4%) | — |
| 2020 | $5.0m (15.0%) | $-46.3m (58.5%) | $-37.5m (27.8%) | -922.0% (63.9%) | — |
| 2021 | $8.0m (58.9%) | $-55.4m (-19.6%) | $-49.6m (-32.3%) | -693.9% (24.7%) | $-0.83 |
| 2022 | $28.3m (255.1%) | $-50.4m (8.9%) | $-26.1m (47.5%) | -178.0% (74.3%) | $-0.46 (44.6%) |
| 2023 | $13.2m (-53.5%) | $-52.9m (-4.9%) | $-63.1m (-142.4%) | -401.6% (-125.6%) | $-0.44 (4.3%) |
| 2024 | $4.5m (-66.0%) | $-50.8m (4.0%) | $-47.2m (25.2%) | -1133.0% (-182.2%) | $-0.38 (13.6%) |
| 2025 | $10.2m (128.2%) | $-24.3m (52.1%) | $-28.8m (39.1%) | -237.9% (79.0%) | $-0.17 (55.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in CAD. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Net debt deduction: —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.